Neuropsychiatric Risks of COVID: New Data

The neuropsychiatric ramifications of severe COVID-19 infection appear to be no different than for other severe acute respiratory infections (SARI). Results of a large study showed risks of new neuropsychiatric illness were significantly and similarly in adults surviving either severe COVID-19 infection or other SARI, compared with the general population. This suggests that disease severity, … Read more

Medical Home Model Improves Mental Health Treatment

A medical home that provides conventional primary care with a focus on mental health appears to be an effective model for managing patients with serious psychiatric illnesses, new research has found. Patients with serious mental illnesses such as schizophrenia and bipolar disorder die at rates 2.2 times higher than the general population. But people with … Read more

High Suicide, Depression Risks for Patients With Cancer

Living with cancer can be emotionally devastating. Now, two expansive studies underscore the scale of the burden a cancer diagnosis and treatment can have on patients’ mental health and risk of suicide. In one, a meta-analysis of 28 studies that included more than 22 million patients, researchers found that among people with cancer, the suicide … Read more

Alcohol Dependence Drug the Next Anti-Anxiety Med?

Disulfiram, a US Food and Drug Admiistration (FDA)–approved medication for the treatment of chronic alcohol dependence, shows promise as a potential anxiolytic, early research suggests. Japanese researchers, headed by Akiyoshi Saitoh, PhD, professor in the Department of Pharmacy, Tokyo University of Science, compared the reactions of mice that received a classic anxiolytic agent (diazepam) to … Read more

Microdosing Psychedelics: Untapped Potential in Psychiatry?

In her month-long memoir, A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage, and My Life (Knopf, 2017), author Ayelet Waldman turns herself into a one-woman experiment. Over a single month she takes one tenth of a recreational dose of LSD every third day. She plots her emotions, her … Read more

New Tool Cuts CVD Risk in Patients With Serious Mental Illness

A clinical decision support (CDS) system that can be implemented in primary care reduces cardiovascular risk factors (CV) common in patients with serious mental illness (SMI), new research suggests. Investigators assessed more than 70 primary care clinics that treated close to 9000 patients with SMI. Disorders included schizophrenia, bipolar disorder, and schizoaffective disorder. The clinics … Read more

Common Eye Disorder in Children Tied to Mental Illness

Dr Stacy L. Pines Misaligned eyes in children are associated with an increased prevalence of mental illness, results of a large study suggest. Investigators found children with strabismus or “crossed eyes” had up to a twofold increased risk of developing anxiety, depression, bipolar disorder, and schizophrenia compared to their counterparts without the eye condition. “Psychiatrists … Read more

Major Mental Illness Linked to Higher CVD Risk, Even in Young

Serious mental illnesses such as bipolar disorder and schizophrenia are associated with a significant increase in cardiovascular risk, particularly among younger age groups, a new observational study suggests. Prior research has shown that people with schizophrenia and bipolar disorder die 10 to 20 years earlier than those without serious mental illness and that the leading … Read more

HIV and Schizophrenia: Partners in Disparities

“People don’t think about schizophrenia when they think about HIV,” Christina Mangurian, MD, professor of clinical psychiatry and vice chair for diversity and health equity at the University of California-San Francisco (UCSF), told Medscape Medical News. The problem is complicated. According to the Centers for Disease Control and Prevention and the National Institutes of Health, … Read more

Sublingual Dexmedetomidine May Rapidly Calm Bipolar Agitation

An investigational, orally dissolving formulation film of dexmedetomidine (BXCL501, BioXcel Therapeutics) can rapidly relieve mild to moderate acute agitation in patients with bipolar disorder (BD), new research suggests. The phase 3 SERENITY II trial included almost 400 adults with bipolar I or II disorder and acute agitation. Results showed relief from acute agitation kicked in … Read more